The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
 
Gyorgy Bodoky
Consulting or Advisory Role - Amgen; Bayer; Janssen Oncology; Lilly; Nordic Group; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Bayer; Nordic Group; Roche
Travel, Accommodations, Expenses - Janssen; Novartis; Roche
 
Marian Gil-Delgado
No Relationships to Disclose
 
Stefano Cascinu
No Relationships to Disclose
 
Oleg N. Lipatov
No Relationships to Disclose
 
David Cunningham
Research Funding - Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Sanofi (Inst)
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Kei Muro
Speakers' Bureau - Taiho Pharmaceutical
 
Kumari Chandrawansa
Employment - Lilly
 
Astra M. Liepa
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Roberto Carlesi
No Relationships to Disclose
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Bayer Yakuhin
 
Hansjochen Wilke
Honoraria - Lilly
Consulting or Advisory Role - Lilly